Looking back to 43 days ago, Halozyme Therapeutics (HALO) priced a 7,692,307 share secondary stock offering at $13.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday, the stock is now 6.4% higher than the offering price.Investors who did not participate in the offering but would be a buyer of HALO at a cheaper price, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $8 strike, which has a bid at the time of this writing of $1.50. That would result in a cost basis of $6.50 per share before broker commissions in the scenario where the contract is exercised. If the contract is never exercised, the put seller would still keep the premium, which represents a 18.8% return against the $8.00 purchase commitment, or a 10.3% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Use Options For a Chance To Buy HALO at a 54% Discount
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts